was confirmed by selective perturbation of the hepatic sensory afferents to the left nodose ganglion not the dorsal root ganglion. Accordingly, left but not right vagal stimulation was essential for maintaining intestinal T<sub>T<sub>reg</sub></sub> cells and aldehyde dehydrogenase activity in APCs.

Genetic ablation of mAChR signalling by the parasympathetic neurotransmitter acetylcholine, but not abrogation of signalling by the sympathetic neurotransmitter noradrenaline, in intestinal APCs also reduced T<sub>T<sub>reg</sub></sub> cells in the colon. Accordingly, treatment with a mAChR agonist restored aldehyde dehydrogenase expression by APCs and colonic T<sub>T<sub>reg</sub></sub> cell frequency in HVx mice, which suggests that the liver–brain–gut reflex, independent of the sympathetic system, creates the intestinal T<sub>T<sub>reg</sub></sub> cell niche.

Finally, although HVx did not cause notable changes in gut microbiome diversity or composition, tonic microbial signals were required for functioning of the liver–brain–gut neural arc, as antibiotic–treated mice and Myd88-knockout mice did not develop worse colitis after HVx.

In summary, the liver–brain–gut neural arc — connecting the hepatic vagal sensory afferents, the brainstem, vagal efferents and enteric neurons to mAChR<sup>+</sup> APCs — serves as a feedback loop to protect the intestine from excessive inflammation.

Lucy Bird

To confirm these findings in vivo, the authors used various HVx knock-in mice. Mice lack the B30.2 domain of human pyrin that contains the HVx mutations (including MEFV<sub>p.M680I</sub>). Therefore, the authors compared systemic Y. pestis infection in Mefv<sup>B30.2/B30.2</sup> and Mefv<sup>M680I/M680I</sup> knock-in mice — they found that the latter showed significantly increased survival. By contrast, IL-1 receptor–deficient Mefv<sup>ME680I/ME680I</sup> mice were highly susceptible to Y. pestis infection. This indicates that HVx-associated mutant pyrin provides a survival advantage during Y. pestis infection that is mediated by the IL-1<sup>+</sup> signalling pathway.

Of note, the two major plague pandemics of 541 CE and 1347 CE were rooted in the Middle East and Mediterranean basin, which may explain why HVx-associated pyrin variants are so common among these populations.

Yvonne Bordon

---

**COVID-19**

**COVID-19 and influenza: preparing for the storm**

The basis of the varied immune responses seen to SARS-CoV-2 and other respiratory infections remains unclear. This preprint by Mudd et al. used single-cell RNA sequencing of PBMCs from patients with COVID-19 or influenza to ascertain disease-specific signatures. The authors identified two select cytokine modules (namely, IL-1RA and IL-6) that correlated with COVID-19 disease severity and were predictive of poor outcomes. By contrast, patients with influenza exhibited higher generalized inflammation. Compared with patients with influenza, patients with COVID-19 had reduced monocyte subsets, as well as lymphopenia, and exhibited a suppressed type I interferon response across multiple immune cell types. Interestingly, these cells, and especially the monocytes, showed enriched glucocorticoid and metabolic stress signalling. These data provide key insights that may guide the design of disease-specific therapies before the start of a new flu season.

**ORIGINAL ARTICLE** Mudd, F.A. et al. Targeted immunosuppression distinguishes COVID-19 from influenza in moderate and severe disease. Preprint at medRxiv https://doi.org/10.1101/2020.05.28.20115667 (2020)

---

**COVID-19**

**SARS-CoV-2-specific T cells without antibodies**

In this preprint, Gallais et al. investigated humoral and cellular immune responses to SARS-CoV-2 in 9 index and 8 contact patients from 7 households. All index patients developed SARS-CoV-2-specific antibodies and T cells, with the responses directed against multiple structural and accessory proteins. However, none of the contact patients had detectable antibodies to SARS-CoV-2. Despite the lack of seroconversion, SARS-CoV-2-specific T cells were detected in 6 contact patients at similar frequencies to index patients. This suggests that testing for SARS-CoV-2-specific T cells may be better than serological tests for assessing prior infection and immunity to SARS-CoV-2. However, further study is warranted to rule out cross-reactivity with prior coronavirus infections.

**ORIGINAL ARTICLE** Gallais, F. et al. Intrahousehold exposure to SARS-CoV-2 induces cellular immune response without seroconversion. Preprint at medRxiv https://doi.org/10.1101/2020.06.21.20134449 (2020)

---

**COVID-19**

**Dexamethasone to the rescue**

In this preprint study of the RECOVERY clinical trial involving 6,425 hospitalized patients with COVID-19, Horby et al. report that patients receiving a 6 mg daily dose of the corticosteroid dexamethasone had a reduced 28-day mortality compared with those receiving standard of care. Importantly, dexamethasone reduced death by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients requiring oxygen but showed no benefit in patients who did not require respiratory support. Overall, the results of this study suggest that dexamethasone, an inexpensive and widely available anti-inflammatory drug, is a valuable treatment for severe cases of COVID-19.

**ORIGINAL ARTICLE** Horby, P. et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. Preprint at medRxiv https://doi.org/10.1101/2020.06.22.20137273 (2020)

Matthew D. Park, Canus Cimen Bokkus and Chang Moon
SinaI Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA
e-mail: sinal.immunology@gmail.com
The authors declare no competing interests.